Nasdaq · CIK 0000906709
NKTR NEKTAR THERAPEUTICS
Insider trading from SEC Form 4. Last filing 17 d ago. Close $41.17 on Oct 9, 2026, +17% from the 52-week low and -59% from the high.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
8
with a Form 4 at this company
Price and insider trades, last year
NKTROct 9, 2026 · close 41.17
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at NEKTAR THERAPEUTICS, scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 32Weak | Howard W Robin President & CEO sell | $311k 6,666 shares | -12% | +561% from low0% from high | |
| 35Weak | Howard W Robin President & CEO sell | $431k 11,832 shares | -17% | +390% from low0% from high | |
| 10Weak | Jonathan Zalevsky Chief R&D Officer sell | $58k 1,721 shares | -9% | +390% from low0% from high | |
| 26Weak | Howard W Robin President & CEO sell | $45k 1,500 shares | -2% | +296% from low-3% from high | |
| 10Weak | Jonathan Zalevsky Chief R&D Officer sell | $15k 485 shares | -2% | +296% from low-3% from high | |
| 46Moderate | Howard W Robin President & CEO sell | $42k 1,573 shares | -2% | +264% from low-10% from high | |
| 30Weak | Mark Andrew Wilson Chief Legal Officer sell | $18k 676 shares | -3% | +264% from low-10% from high | |
| 30Weak | Jonathan Zalevsky Chief R&D Officer sell | $19k 725 shares | -4% | +264% from low-10% from high | |
| 40Moderate | Howard W Robin President & CEO sell | $16k 23,208 shares | -2% | +43% from low-52% from high | |
| 30Weak | Mark Andrew Wilson Chief Legal Officer sell | $6,697 9,996 shares | -3% | +43% from low-52% from high | |
| 30Weak | Jonathan Zalevsky Chief R&D Officer sell | $7,177 10,712 shares | -3% | +43% from low-52% from high | |
| 41Moderate | Mark Andrew Wilson Chief Legal Officer sell | $45k 49,962 shares | -13% | - | |
| 42Moderate | Jonathan Zalevsky Chief R&D Officer sell | $48k 51,115 shares | -14% | - | |
| 56Moderate | Howard W Robin President & CEO sell | $132k 132,030 shares | -11% | - | |
| 40Moderate | Howard W Robin President & CEO sell | $16k 16,278 shares | -2% | - | |
| 30Weak | Mark Andrew Wilson Chief Legal Officer sell | $6,471 6,407 shares | -3% | - | |
| 30Weak | Jonathan Zalevsky Chief R&D Officer sell | $7,863 7,785 shares | -3% | - |
Transactions
The last 56 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 23, 2026 | Jeffrey Robert Ajer director | AGrant or award Common Stock | +2,000 | $0.00 | $0 | 4,277 | 17 d ago |
| Sep 23, 2026 | Diana Brainard director | AGrant or award Common Stock | +2,000 | $0.00 | $0 | 3,904 | 17 d ago |
| Sep 23, 2026 | Roy A Whitfield director | AGrant or award Common Stock | +2,000 | $0.00 | $0 | 16,417 | 17 d ago |
| Sep 23, 2026 | Robert Chess director | AGrant or award Common Stock | +2,000 | $0.00 | $0 | 19,019 | 17 d ago |
| Sep 23, 2026 | R Scott Greer director | AGrant or award Common Stock | +2,000 | $0.00 | $0 | 22,239 | 17 d ago |
| Sep 23, 2026 | Jeffrey Robert Ajer director | AGrant or award Stock Optionderivative | +4,000 | $0.00 | $0 | 4,000 | 17 d ago |
| Sep 23, 2026 | R Scott Greer director | AGrant or award Stock Optionderivative | +4,000 | $0.00 | $0 | 4,000 | 17 d ago |
| Sep 23, 2026 | Diana Brainard director | AGrant or award Stock Optionderivative | +4,000 | $0.00 | $0 | 4,000 | 17 d ago |
| Sep 23, 2026 | Roy A Whitfield director | AGrant or award Stock Optionderivative | +4,000 | $0.00 | $0 | 4,000 | 17 d ago |
| Sep 23, 2026 | Robert Chess director | AGrant or award Stock Optionderivative | +4,000 | $0.00 | $0 | 4,000 | 17 d ago |
| Sep 30, 2025 | Jeffrey Robert Ajer director | AGrant or award Stock Optionderivative | +8,000 | $0.00 | $0 | 8,000 | Oct 1, 2025 |
| Sep 30, 2025 | Diana Brainard director | AGrant or award Stock Optionderivative | +8,000 | $0.00 | $0 | 8,000 | Oct 1, 2025 |
| Sep 30, 2025 | Robert Chess director | AGrant or award Stock Optionderivative | +8,000 | $0.00 | $0 | 8,000 | Oct 1, 2025 |
| Sep 9, 2025 | Howard W Robin President & CEO | SOpen-market sale Common Stock10b5-1 | -2,100 | $45.16 | $95k | 53,908 | Sep 11, 2025 |
| Sep 9, 2025 | Howard W Robin President & CEO | SOpen-market sale Common Stock10b5-1 | -1,200 | $46.41 | $56k | 52,708 | Sep 11, 2025 |
| Sep 9, 2025 | Howard W Robin President & CEO | SOpen-market sale Common Stock10b5-1 | -2,156 | $47.49 | $102k | 50,552 | Sep 11, 2025 |
| Sep 9, 2025 | Howard W Robin President & CEO | SOpen-market sale Common Stock10b5-1 | -1,210 | $48.18 | $58k | 49,342 | Sep 11, 2025 |
| Sep 4, 2025 | Jonathan Zalevsky Chief R&D Officer | SOpen-market sale Common Stock10b5-1 | -793 | $32.43 | $26k | 18,390 | Sep 8, 2025 |
| Sep 4, 2025 | Howard W Robin President & CEO | SOpen-market sale Common Stock10b5-1 | -1,923 | $32.37 | $62k | 65,917 | Sep 8, 2025 |
| Sep 4, 2025 | Jonathan Zalevsky Chief R&D Officer | SOpen-market sale Common Stock10b5-1 | -432 | $33.60 | $15k | 17,958 | Sep 8, 2025 |
| Sep 4, 2025 | Howard W Robin President & CEO | SOpen-market sale Common Stock10b5-1 | -1,496 | $33.54 | $50k | 64,421 | Sep 8, 2025 |
| Sep 4, 2025 | Jonathan Zalevsky Chief R&D Officer | SOpen-market sale Common Stock10b5-1 | -189 | $34.41 | $6,503 | 17,769 | Sep 8, 2025 |
| Sep 4, 2025 | Howard W Robin President & CEO | SOpen-market sale Common Stock10b5-1 | -613 | $34.40 | $21k | 63,808 | Sep 8, 2025 |
| Sep 4, 2025 | Howard W Robin President & CEO | SOpen-market sale Common Stock10b5-1 | -1,134 | $35.80 | $41k | 62,674 | Sep 8, 2025 |
| Sep 4, 2025 | Jonathan Zalevsky Chief R&D Officer | SOpen-market sale Common Stock10b5-1 | -307 | $35.69 | $11k | 17,462 | Sep 8, 2025 |
| Sep 5, 2025 | Howard W Robin President & CEO | SOpen-market sale Common Stock10b5-1 | -3,304 | $37.87 | $125k | 59,370 | Sep 8, 2025 |
| Sep 5, 2025 | Howard W Robin President & CEO | SOpen-market sale Common Stock10b5-1 | -2,226 | $38.82 | $86k | 57,144 | Sep 8, 2025 |
| Sep 5, 2025 | Howard W Robin President & CEO | SOpen-market sale Common Stock10b5-1 | -1,136 | $39.89 | $45k | 56,008 | Sep 8, 2025 |
| Sep 2, 2025 | Howard W Robin President & CEO | SOpen-market sale Common Stock10b5-1 | -1,500 | $30.16 | $45k | 67,840 | Sep 4, 2025 |
| Sep 2, 2025 | Jonathan Zalevsky Chief R&D Officer | SOpen-market sale Common Stock10b5-1 | -485 | $30.10 | $15k | 19,183 | Sep 4, 2025 |
| Aug 19, 2025 | Howard W Robin President & CEO | SOpen-market sale Common Stock | -1,573 | $26.59 | $42k | 69,340 | Aug 21, 2025 |
| Aug 19, 2025 | Mark Andrew Wilson Chief Legal Officer | SOpen-market sale Common Stock | -676 | $26.59 | $18k | 20,312 | Aug 21, 2025 |
| Aug 19, 2025 | Jonathan Zalevsky Chief R&D Officer | SOpen-market sale Common Stock | -725 | $26.59 | $19k | 19,668 | Aug 21, 2025 |
| Aug 19, 2025 | Mark Andrew Wilson Chief Legal Officer | AGrant or award Stock Optionderivative | +21,666 | $0.00 | $0 | 21,666 | Aug 21, 2025 |
| Aug 19, 2025 | Jonathan Zalevsky Chief R&D Officer | AGrant or award Stock Optionderivative | +16,666 | $0.00 | $0 | 16,666 | Aug 21, 2025 |
| Aug 19, 2025 | Howard W Robin President & CEO | AGrant or award Stock Optionderivative | +86,666 | $0.00 | $0 | 86,666 | Aug 21, 2025 |
| May 19, 2025 | Howard W Robin President & CEO | SOpen-market sale Common Stock | -23,208 | $0.67 | $16k | 1,063,693 | May 21, 2025 |
| May 19, 2025 | Mark Andrew Wilson Chief Legal Officer | SOpen-market sale Common Stock | -9,996 | $0.67 | $6,697 | 314,296 | May 21, 2025 |
| May 19, 2025 | Jonathan Zalevsky Chief R&D Officer | SOpen-market sale Common Stock | -10,712 | $0.67 | $7,177 | 305,892 | May 21, 2025 |
| Dec 23, 2024 | Mark Andrew Wilson Chief Legal Officer | SOpen-market sale Common Stock | -33,402 | $0.90 | $30k | 351,892 | Dec 26, 2024 |
| Dec 24, 2024 | Mark Andrew Wilson Chief Legal Officer | SOpen-market sale Common Stock | -16,560 | $0.89 | $15k | 335,332 | Dec 26, 2024 |
| Dec 19, 2024 | Jonathan Zalevsky Chief R&D Officer | SOpen-market sale Common Stock | -51,115 | $0.94 | $48k | 326,904 | Dec 20, 2024 |
| Dec 17, 2024 | Howard W Robin President & CEO | SOpen-market sale Common Stock | -46,995 | $1.01 | $47k | 1,195,710 | Dec 19, 2024 |
| Dec 18, 2024 | Howard W Robin President & CEO | SOpen-market sale Common Stock | -85,035 | $0.99 | $84k | 1,110,675 | Dec 19, 2024 |
| Dec 13, 2024 | Howard W Robin President & CEO | AGrant or award Common Stock | +410,625 | $0.00 | $0 | 1,242,705 | Dec 17, 2024 |
| Dec 13, 2024 | Mark Andrew Wilson Chief Legal Officer | AGrant or award Common Stock | +165,938 | $0.00 | $0 | 385,294 | Dec 17, 2024 |
| Dec 13, 2024 | Jonathan Zalevsky Chief R&D Officer | AGrant or award Common Stock | +135,000 | $0.00 | $0 | 378,019 | Dec 17, 2024 |
| Dec 13, 2024 | Mark Andrew Wilson Chief Legal Officer | AGrant or award Stock Optionderivative | +331,875 | $0.00 | $0 | 331,875 | Dec 17, 2024 |
| Dec 13, 2024 | Jonathan Zalevsky Chief R&D Officer | AGrant or award Stock Optionderivative | +270,000 | $0.00 | $0 | 270,000 | Dec 17, 2024 |
| Dec 13, 2024 | Howard W Robin President & CEO | AGrant or award Stock Optionderivative | +821,250 | $0.00 | $0 | 821,250 | Dec 17, 2024 |
| Dec 13, 2024 | Mark Andrew Wilson Chief Legal Officer | AGrant or award Stock Optionderivative | +325,000 | $0.00 | $0 | 325,000 | Dec 17, 2024 |
| Dec 13, 2024 | Jonathan Zalevsky Chief R&D Officer | AGrant or award Stock Optionderivative | +375,000 | $0.00 | $0 | 375,000 | Dec 17, 2024 |
| Dec 13, 2024 | Howard W Robin President & CEO | AGrant or award Stock Optionderivative | +1,300,000 | $0.00 | $0 | 1,300,000 | Dec 17, 2024 |
| Nov 19, 2024 | Howard W Robin President & CEO | SOpen-market sale Common Stock | -16,278 | $1.01 | $16k | 832,080 | Nov 20, 2024 |
| Nov 19, 2024 | Mark Andrew Wilson Chief Legal Officer | SOpen-market sale Common Stock | -6,407 | $1.01 | $6,471 | 218,856 | Nov 20, 2024 |
| Nov 19, 2024 | Jonathan Zalevsky Chief R&D Officer | SOpen-market sale Common Stock | -7,785 | $1.01 | $7,863 | 243,019 | Nov 20, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Jeffrey Robert Ajerdirector
- Diana Brainardceo, officer, director
- Robert Chessdirector
- R Scott Greerdirector
- Howard W RobinPresident & CEO
- Roy A Whitfielddirector
- Mark Andrew WilsonChief Legal Officer
- Jonathan ZalevskyChief R&D Officer
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.